Nomenclature of Fatty Acids
“C-“: chain length (short 2-4, medium 6-12, long 14-18, 20 and greater)
Saturation: # of duble bonds (saturated = NO souble bonds)
Conjugated Dienes
Conjugated fatty acids produced by rumen microbes, each double bond separated by a single bond (rather than a methylene group)
most common: cis-9, trans 11-18:2 (called Conjugated Linoleic acids)
Nutrition chemical system of fatty acids
number of carbon:number of double bonds, number after the n/omega is location of double bonds counting from the methyl end (normally in other field, uses delta which counts from the carboxyl end)
e.g. C20:4 n6
Unsaturated Fatty Acid Families and their n number (location of double bond)
Essential Fatty Acids
Linoleic Acid Deficiency
Linoleic Acid (omega 6): Required for normal growth, skin health, and cellular function
Essential for ceramide synthesis, which maintains the skin’s water barrier. Deficiency causes: Scaly skin, Poor wound healing, Increased water loss
Functions of Essential Fatty Acids
Eicosanoids
Hormones that work on cells that produced them or cells closed to them (act locally, short half-life)
Derived from n-3 and n-6
Main: prostaglandins (PGE2)→ vasoldilation/inflammation thromboxanes (TXA2) → vasoconstrition/clotting, and leukotrienes (LTB4)
Precursors: n-6 (arachidonic acid) and n-3 (eicosapentaenoic acid) fatty acids
Functions of n-6 vs n-3 derived Eicosanoids
n-6: pro-inflamatory → PGE2: increased vascular permeablity, increased COX 2/IL-6; TXA2: Vascontriction/clotting/platelets aggregation; LTB4: inflammation induction/ ROS/ neutrophils
n-3: generally anti-inflammatory → weak inducers **form protectins and resolvins: resolution of inflammation
Reasons for adding fats to diet
Cellular Signal Transduction Pharmacodynamics equation for excitability proteins
[L]+[R] ↔ [LR] → [LR] excited →→→ reponsse
Intrinsic efficacy
Drug’s ability to produce a response aka Degree of the excited state: α (alpha)
aka reflects the greatest clinical response attainable with a drug at any dose
[LR] → [LR] excited
Kd
equilibrium dissasociation contant
Lower Kd= higher affinity/binding
**equals to when half of the receptors are occupied
Potency vs Efficacy on graph
Potency: concentration needed to elicit a response → left shif on x-axis = more potent
Efficacy: maximal response → amplitude on y-axis
ED50 and EC50
ED50:
- Drug Dose produces 50% of maximum effect in an individual (Graded relationship)
- Drug Does producing a given effect in 50% of the population (all or none response - Quantal relationship)
EC50:
- Drug concentration producing 50% of the maximum effect (in vitro)
Agonist vs Partial Agonist vs Antagonist
Agonist: binds to active receptor and stimulates a maximal response characteristic of that receptor (promotes ongoing responses) 1.0>alpha>0.8
Partial Agonist: stimulates the receptor to produce a response, but not to the same extent as a full agonist (submaximal response) 0.8>alpha>0.2
Antagonist: Do not alter receptor activity on their own but can compete with agonists for receptor binding, thus competitively blocking the responses elicited by the agonist (inhibit responses)
Graded vs Quantal Relationships
Graded: continuous scale; measured in a single biologic unit; relates does to intensity of effect (greater the dose, greater the intensity of the effect) → half the maximal response in an individual
Quantal: all-or-none pharmacologic effect; population studies; related dose to frequency of effect → half the maximal response in a population
Therapeutic Index (TI)
TD50/ED50
High TI → wide safety margin → safer drug
Low TI → narrow safety margin → riskier drug
Clinal potency
the amount of drug needed to produce a certain level of therapeutic response -aka- a drug’s affinity for its receptor
what is magnitude if a response proportional to
proportional to the fraction of receptor sites (R) complexed with a reversible ligand (L)
Inverse agonist
ligand that binds to the same receptor as the agonist and causes the opposite effect of the agonist ligand (efficacy is less than 0)
Competitive antagonist
Antagonism can be overcome by increasing agonist concentration
** Right shift curve due to competitive antagonism (increase conc. & same efficacy) **
Schild plot slope= -1
Kb= disassociation constant of an antagonist
Noncompetitve antagonism
Bind another site on same receptor (allosteric site) & reduce the magnitude of maximum response that can be attained by any amount of agonist → decrease efficacy (lower curve on y-axis)
**effects can’t be overcome with incrasing agonist concentration
Drug-drug interactions effect
I. Increased effect: Increased therapeutic effect & increased toxic or adverse effect
- Additive: both drug actions together equals the sum of actions of each drug when administered alone
- Synergistic: promote an exaggerated effect out of proportion compared to each drug alone
II. Decreased effect: antagonistic effect (one drug inhibits action of another)
→ decreased therapeutic effect & decrease toxic effect